MUSCARINIC CHOLINERGIC HYPERACTIVITY IN SCHIZOPHRENIA - RELATIONSHIP TO POSITIVE AND NEGATIVE SYMPTOMS

被引:105
作者
TANDON, R
SHIPLEY, JE
GREDEN, JF
MANN, NA
EISNER, WH
GOODSON, J
机构
[1] UNIV MICHIGAN,MED CTR,DEPT PSYCHIAT,ANN ARBOR,MI 48109
[2] UNIV MICHIGAN,MED CTR,SLEEP DIAGNOST & RES PROGRAM,ANN ARBOR,MI 48109
关键词
CHOLINERGIC; SYMPTOMS; PSYCHOTIC; PHARMACOLOGY; SLEEP; (SCHIZOPHRENIA);
D O I
10.1016/0920-9964(91)90006-D
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Based on the implication of increased muscarinic ACh activity in the production of negative symptoms, the association of decreasing cholinergic activity with positive symptoms, and the covariance of positive and negative symptoms in the psychotic phase of schizophrenia, a model of (DA) dopaminergic/(ACh) cholinergic interactions in schizophrenia was recently formulated. It suggests that DA/ACh balance is of central importance in schizophrenic pathophysiology and that muscarinic ACh activity increases in an attempt to maintain this balance in the face of increasing DA activity that occurs in the psychotic phase of the illness. The model further suggests that the muscarinic system exerts a damping influence on the emergence of positive symptoms associated with DA hyperactivity, but that this compensatory increase in muscarinic activity is accompanied by an intensification of negative symptoms. In the present study, we tested two important postulates of this model. We tested the prediction that muscarinic activity is increased in schizophrenia by comparing the effect of biperiden, an antimuscarinic M-1 agent, on REM latency in 12 drug-free schizophrenic inpatients and matched normal controls. We found that biperiden caused a smaller increase in REM latency in schizophrenic patients, suggesting that muscarinic activity is increased in schizophrenia. We tested the prediction that an anticholinergic agent would increase positive symptoms and decrease negative symptoms by studying the effect of 8 mg of biperiden/day for 2 days on positive and negative symptoms (assessed by the BPRS) in 30 medication-free schizophrenic inpatients. Biperiden produced a significant increase in positive symptoms (t = 6.36, df = 29, P < 0.001) and reduction in negative symptoms (t = -2.05, df = 29, P < 0.05). These findings suggest that central muscarinic activity is increased in the psychotic phase of schizophrenia and is relevant to the expression of positive and negative symptoms.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 48 条
[1]   BENNETT,AE AWARD PAPER MUSCARINIC RECEPTOR SUBCLASSIFICATION AND G-PROTEINS - SIGNIFICANCE FOR LITHIUM ACTION IN AFFECTIVE-DISORDERS AND FOR THE TREATMENT OF THE EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS [J].
AVISSAR, S ;
SCHREIBER, G .
BIOLOGICAL PSYCHIATRY, 1989, 26 (02) :113-130
[2]  
BARABAN JM, 1989, AM J PSYCHIAT, V146, P1251
[3]  
BERGER M, 1989, ARCH GEN PSYCHIAT, V46, P421
[4]  
BERGER M, 1989, BIOL PSYCHIATRY 1988
[5]   IDENTIFICATION OF A FAMILY OF MUSCARINIC ACETYLCHOLINE-RECEPTOR GENES [J].
BONNER, TI ;
BUCKLEY, NJ ;
YOUNG, AC ;
BRANN, MR .
SCIENCE, 1987, 237 (4814) :527-532
[6]   NEUROTRANSMITTER STUDIES OF NEUROENDOCRINE PATHOLOGY IN DEPRESSION [J].
CARROLL, BJ ;
GREDEN, JF ;
HASKETT, R ;
FEINBERG, M ;
ALBALA, AA ;
MARTIN, FIR ;
RUBIN, RT ;
HEATH, B ;
SHARP, PT ;
MCLEOD, WL ;
MCLEOD, MF .
ACTA PSYCHIATRICA SCANDINAVICA, 1980, 61 :183-199
[7]   Acetylcholine treatment of schizophrenia [J].
Cohen, LH ;
Thall, T ;
Tissenbaum, MJ .
ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 1944, 51 (02) :171-175
[8]   PHYSOSTIGMINE - EFFECTS ON COGNITION AND AFFECT IN NORMAL SUBJECTS [J].
DAVIS, KL ;
HOLLISTER, LE ;
OVERALL, J ;
JOHNSON, A ;
TRAIN, K .
PSYCHOPHARMACOLOGY, 1976, 51 (01) :23-27
[9]  
DOGLASS AB, 1989, BIOL PSYCHIAT, V25, pA203
[10]  
DOMINO EF, 1973, ARCH GEN PSYCHIAT, V29, P195